Patent US4349538A successfully refreshed from Google Patents.
US4349538A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
Assignee: United States, HEALTH AND HUMAN RESOURCES Inc, Secretary of, Department of
•
Filing: 1980-11-18
•
Granted: 1982-09-14
•
Expires: 2000-11-18
Abstract
Abstract A nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid, poly-1-lysine, and carboxymethylcellulose, and injectable preparations thereof in a pharmaceutically acceptable aqueous carrier such as saline solution. When administered to a human or non-human primate host, the complex is effective in inducing the synthesis in such host of antiviral levels of interferon.
Inventors
- 👤 Hilton B. Levy
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 03:30
CPC Classifications
C; C07; C07H; C07H21/00
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
30 words
A nuclease-resistant hydrophilic complex of: relatively high molecular weight polyriboinosinic-polyribocytidylic acid; relatively low molecular weight poly-1-lysine in a range of from about 13,000 daltons to about 35,000 daltons; and carboxymethylcellulose.
Claim 2
Dependent Claim
30 words
A nuclease-resistant hydrophilic complex of: relatively high molecular weight polyriboinosinic-polyribocytidylic acid; relatively low molecular weight poly-1-lysine in a range of from about 13,000 daltons to about 35,000 daltons; and carboxymethylcellulose.
Claim 3
Dependent Claim
27 words
The complex of claim 1 wherein said polyriboinosinic-polyribocytidylic acid has a molecular weight in the range of from about 7×10 5 daltons to about 1×10 7 daltons.
Claim 4
Dependent Claim
21 words
The complex of claim 2 wherein the poly-1-lysine has a molecular weight of from about 17,000 daltons to about 28,000 daltons.
Claim 5
Dependent Claim
21 words
The complex of claim 3 wherein the poly-1-lysine has a molecular weight of from about 27,000 daltons to about 28,000 daltons.
Claim 6
Dependent Claim
35 words
An injectable preparation in a pharmaceutically acceptable carrier of the complex of claim 1 whose unit dosage is sufficient to induce the synthesis of interferon in a mammal into which it is to be injected.
Claim 7
Dependent Claim
35 words
An injectable preparation in a pharmaceutically acceptable carrier of the complex of claim 3 whose unit dosage is sufficient to induce the synthesis of interferon in a mammal into which it is to be injected.
Claim 8
Dependent Claim
35 words
An injectable preparation in a pharmaceutically acceptable carrier of the complex of claim 4 whose unit dosage is sufficient to induce the synthesis of interferon in a mammal into which it is to be injected.
Claim 9
Dependent Claim
30 words
The preparation of claim 6 containing 1 to 4 mg/ml of said polyriboinosinic-polyribocytidylic acid, 0.75 to 3 mg/ml of poly-1-lysine and 0.25 to 1 percent by weight of said carboxymethylcellulose.
Claim 10
Dependent Claim
25 words
The preparation of claim 8 containing 2 mg/ml of said polyriboinosinic-polyribocytidylic acid, 1.5 mg/ml of said poly-1-lysine and 0.5 percent by weight of said carboxymethylcellulose.
Claim 11
Dependent Claim
11 words
The preparation of claim 8 wherein said carrier is saline solution.
Claim 12
Independent Claim
61 words
A method of inducing the synthesis of interferon in a primate which comprises administering to a primate host a nuclease-resistant hydrophilic complex of relatively high molecular weight polyriboinosinic-polyribocytidylic acid, relatively low molecular weight poly-1-lysine in a range of from about 13,000 daltons to about 35,000 daltons, and carboxymethylcellulose, in a dose sufficient to provide an interferon-inducing amount of said polyriboinosinic-polyribocytidylic acid.
Claim 13
Independent Claim
61 words
A method of inducing the synthesis of interferon in a primate which comprises administering to a primate host a nuclease-resistant hydrophilic complex of relatively high molecular weight polyriboinosinic-polyribocytidylic acid, relatively low molecular weight poly-1-lysine in a range of from about 13,000 daltons to about 35,000 daltons, and carboxymethylcellulose, in a dose sufficient to provide an interferon-inducing amount of said polyriboinosinic-polyribocytidylic acid.
Claim 14
Dependent Claim
21 words
The method of claim 11 wherein the poly-1-lysine has a molecular weight of from about 17,000 daltons to about 28,000 daltons.
Claim 15
Dependent Claim
21 words
The method of claim 12 wherein the poly-1-lysine has a molecular weight of from about 27,000 daltons to about 28,000 daltons.
Claim 16
Dependent Claim
45 words
The method of claim 12 wherein said host is a non-human primate and said complex is administered from every other day to daily in a dose sufficient to provide from about 1 to about 5 mg of said polyriboinosinic-polyribocytidylic acid per kg of body weight.
Claim 17
Dependent Claim
34 words
The method of claim 14 wherein said complex is administered from every other day to daily in a dose sufficient to provide about 3 mg of said polyriboinosinic-polyribocytidylic acid per kg of body weight.
Claim 18
Dependent Claim
46 words
The method of claim 11, 12 or 13 wherein said host is a human and said complex is administered from every other day to daily in a dose sufficient to provide from about 0.3 to 2 mg of said polyriboinosinic-polyribocytidylic acid per kg of body weight.
Claim 19
Dependent Claim
34 words
The method of claim 16 wherein said complex is administered from every other day to daily in a dose sufficient to provide about 1 mg of said polyriboinosinic-polyribocytidylic acid per kg of body weight.
Claim 20
Dependent Claim
17 words
The method of claim 11 wherein the poly-1-lysine molecular weight is from about 13,000 to 28,000 daltons.
Claim 21
Dependent Claim
17 words
The complex of claim 1 wherein the poly-1-lysine molecular weight is from about 13,000 to 28,000 daltons.
References Cited (Backward Citations)
US4024241A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-09-13 | 1986-03-15 | 1986-09-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-09-13 | 1990-03-15 | 1990-09-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-09-13 | 1994-03-15 | 1994-09-14 | $7700.00 | Window Closed / Lapsed |